Immediate Impact
1 standout
Citing Papers
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2023 Standout
Works of U. Dernedde being referenced
P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| U. Dernedde | 9 | 11 | 1 | 3 | 5 | 17 | |
| A. Mayer-da-Silva | 12 | 10 | 4 | 16 | |||
| Márton Szentkereszty | 12 | 11 | 5 | 24 | |||
| Timur Andabekov | 8 | 11 | 4 | 13 | |||
| Xin Xiu Sam | 14 | 10 | 4 | 19 | |||
| Till Wallrabenstein | 11 | 20 | 4 | 25 | |||
| Steffi Busch | 8 | 8 | 6 | 16 | |||
| Donald Richards | 5 | 12 | 5 | 21 | |||
| Matthew I. Miller | 7 | 8 | 4 | 16 | |||
| Constanța Mihăescu-Pinţia | 5 | 14 | 4 | 18 | |||
| Mayra Orrillo | 8 | 10 | 6 | 11 |
All Works
Loading papers...